FDA bans all products from Pax-All Manufacturing plant

The Canadian over-the-counter drugmaker Pax-All Manufacturing has been banned by the FDA from shipping any of its products into the U.S. until it cleans up its act.

A warning letter to the Ontario company, which sells to dollar stores, cited loose manufacturing practices and the use of duct tape and cardboard used to fix a problem, reports the Globe and Mail

Mario Merino, Pax-All's vice-president, says the company, which also makes cosmetics, is addressing FDA concerns, but he also called the action "absurd," claiming the FDA was playing favorites. He says he believes facilities in Asia get less oversight than his.

The FDA dismissed his accusation. FDA spokeswoman Shelly Burgess told the Globe and Mail: "We just don't target one company and not others. Someone who has received a warning letter will of course try to deflect the attention away from them."

And if the FDA was going to play favorites, you might expect it to be easier on facilities in the U.S. Merino didn't seem to take into account the Novartis ($NVS) plant in Lincoln, NE, which makes mostly OTC products. It has been closed since December and working to again win FDA approval.

- read the Globe and Mail story

Suggested Articles

McCallum was hit with a warning letter from the FDA for testing issues with its products and failing to keep appropriate records.

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.